5-Fluoro-2-Oxindole CAS 56341-41-4 Puritas >99.0% (LCMS)

Description:

Nomen chemicum: 5-Fluoro-2-Oxindole

CAS: 56341-41-4

Puritas: >99.0% (LCMS)

Aspectus: Lux Yellow Crystallina pulveris

Intermedia Sunitinib Malate (CAS: 341031-54-7)

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Shanghai Ruifu Chemical Co., Ltd. est primarium fabrica et supplementum 5-Fluoro-2-Oxindole (CAS: 56341-41-4) cum magna qualitate, productione commerciali.Gratum ad ordinem.

Chemical Properties:

Nomen chemicum	5-Fluoro-2-Oxindole
Synonyma	5-Fluorooxindole;5-Fluoro-2-indolinone;5-Fluoroindolin-2-unum;5-Fluoro-1,3-Dihydro-indol-2-one
CAS Number	56341-41-4
CATTUS Number	RF-PI1543
Stock Status	In Stock, Productio Ascendite ad Tons
Formulae hypotheticae	C8H6FNO
M. Pondus	151.14
Density	1.311±0.06 g/cm3
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Lux Yellow Crystallina pulveris
1 H NMR Spectrum	Congruunt cum Structure
LCMS	Congruunt cum Structure
Puritas / Analysis Methodus	>99.0% (LCMS)
Liquescens punctum	143.0~ 147.0℃
Damnum in Siccatio	<0.50%
Totalis immunditias	<1.00%
Test Standard	Enterprise Standard
Consuetudinem	Pharmaceutical Intermedia;Sunitinib Malate medium

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris.

Repono Condition:Repone in vasis signatis in loco frigido et sicco;A luce et humore protege.

commoda:

FAQ:

Applicatio:

5-Fluoro-2-Oxindole (CAS: 56341-41-4) maxime in industria pharmaceutica adhibetur sicut intermedium pharmaceuticum.5-Fluoro-2-Oxindole medium est in synthesi Sunitinib Malatis (CAS: 341031-54-7).Sunitinib Malate novum oralis medicamenta multi-iaculatus anticancer est et ad inhibitorem kinasi tyrosinae tyrosinae multi-iaculantis pertinet cum eius artis nomine "Suntent".Feliciter a Societate Pfizer elaboratum est et effectum duplicem anti-tumorem habet.Praeterea unicum medicamentum therapeuticum est quod superare potest 2 annorum tempus superessentiae cancri renis provectioris et partes centrales agit in campo carcinomatis et gastroi stromal tumoris therapeuticis.Intravit in forum mense Februario 2006 in Civitatibus Foederatis.Hoc medicamentum primum anti-cancer medicamentum, quod ab US FDA probatum est, simul duos morbos curare potest.